ANAB
Neutral signalScored 2026-10-06 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
AnaptysBio, Inc.
- Nom
- AnaptysBio, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.4B
- Employés
- 104
- PDG
- Daniel Faga
- Site web
- https://www.anaptysbio.com
- Marché
- ACRSANNXARTVCNTBDNTHIMVT
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 5 000 titres (~249 371,50 $ US)
- Insiders
- RENTON HOLLINGS
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$249,372
Avg sell (VWAP, 90d window) $49.87 vs last close $47.89 (-4.0%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$249,372 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-01
- Liquidity
- Liquid $26,425,357/day · 20d vol
- Last synced
-
2026-10-07 09:54:19
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-01 | RENTON HOLLINGS | Sell · S · 10b5-1 | 5,000 | $49.87 | $249,372 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-06 Drivers: trend, fundamentals. Insiders: neutral. Moteurs : tendance, fondamentaux. Initiés : neutre.
ANAB presents a compelling operational turnaround story with strong liquidity (85) and improving fundamentals (75), supported by a meaningful earnings catalyst tied to Jemperli royalty momentum and FDA priority review…
The first sentence of the analysis written for ANAB on 2026-10-06 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $249K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $249K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 9.07 · operating margin 20%
Suggested stop 42.62, nearest stored support minus 0.5 ATR(11.0% under the last close). Reward/risk to the next stored resistance is 1.22. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 99.0% | -79.5% | -671.0% | -763.2% | -55.9% | |
| Ebit Margin | 28.5% | -104.2% | -915.5% | -1045.9% | -91.5% | |
| Ebitda Margin | 29.5% | -101.6% | -911.7% | -1023.2% | -88.2% | |
| Operating Profit Margin | 20.4% | -125.9% | -958.3% | -1119.4% | -89.9% | |
| Pretax Profit Margin | -5.6% | -159.1% | -953.7% | -1251.1% | -91.5% | |
| Continuous Operations Profit Margin | -5.6% | -159.1% | -953.7% | -1251.3% | -91.5% | |
| Net Profit Margin | -5.6% | -159.1% | -953.7% | -1251.3% | -91.5% | |
| Bottom Line Profit Margin | -5.6% | -159.1% | -953.7% | -1251.3% | -91.5% | |
| Current Ratio | 9.068 | 9.507 | 10.866 | 17.165 | 34.404 | |
| Quick Ratio | 9.068 | 9.507 | 10.866 | 17.165 | 34.404 | |
| Solvency Ratio | -0.033 | -0.346 | -0.447 | -0.363 | -0.194 | |
| Cash Ratio | 6.167 | 2.709 | 0.961 | 2.737 | 30.793 | |
| Price To Earnings Ratio | -70.261 | -1.725 | -2.349 | -4.521 | -10.981 | |
| Price To Earnings Growth Ratio | 0.772 | 0.109 | -0.071 | -0.039 | -0.058 | |
| Forward Price To Earnings Growth Ratio | 0.772 | 0.109 | -0.071 | -0.039 | -0.058 | |
| Price To Earnings Diluted Ratio | -70.261 | -1.725 | -2.349 | -4.521 | -10.981 | |
| Price To Earnings Diluted Growth Ratio | 0.772 | 0.109 | -0.071 | -0.039 | -0.058 | |
| Price To Book Ratio | 24.137 | 3.536 | 4.364 | 2.220 | 1.783 | |
| Price To Sales Ratio | 3.828 | 2.746 | 22.409 | 56.565 | 10.061 | |
| Price To Free Cash Flow Ratio | 45.800 | -1.847 | -3.162 | -7.869 | -13.441 | |
| Price To Operating Cash Flow Ratio | 45.598 | -1.852 | -3.183 | -7.907 | -13.841 | |
| Debt To Assets Ratio | 0.039 | 0.764 | 0.039 | 0.032 | 0.033 | |
| Debt To Equity Ratio | 0.379 | 5.213 | 0.202 | 0.074 | 0.059 | |
| Debt To Capital Ratio | 0.275 | 0.839 | 0.168 | 0.069 | 0.056 | |
| Long Term Debt To Capital Ratio | 0.244 | 0.833 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 9.793 | 6.827 | 5.135 | 2.329 | 1.804 | |
| Working Capital Turnover Ratio | 0.672 | 0.242 | 0.043 | 0.021 | 0.138 | |
| Operating Cash Flow Ratio | 0.510 | -2.979 | -3.226 | -2.825 | -2.852 | |
| Operating Cash Flow Sales Ratio | 0.084 | -1.483 | -7.041 | -7.154 | -0.727 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.996 | 1.003 | 1.007 | 1.005 | 1.030 | |
| Debt Service Coverage Ratio | 0.865 | -1.783 | -8.650 | -4.988 | -38.418 | |
| Interest Coverage Ratio | 0.600 | -2.295 | -9.092 | -5.455 | -39.182 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -70.305 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 1.396 | -0.366 | -6.781 | -3.784 | -2.191 | |
| Capital Expenditure Coverage Ratio | 226.402 | -378.036 | -149.690 | -205.567 | -33.616 | |
| Dividend Paid And Capex Coverage Ratio | 226.402 | -378.036 | -149.690 | -205.567 | -33.616 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 9.734 | -5.359 | -2.342 | -5.036 | -2.887 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 99.0% | ▲178.5% | ▲393.1% |
| Ebit Margin | 28.5% | ▲132.7% | ▲454.2% |
| Ebitda Margin | 29.5% | ▲131.1% | ▲448.6% |
| Operating Profit Margin | 20.4% | ▲146.3% | ▲475.0% |
| Pretax Profit Margin | -5.6% | ▲153.5% | ▲486.6% |
| Continuous Operations Profit Margin | -5.6% | ▲153.5% | ▲486.6% |
| Net Profit Margin | -5.6% | ▲153.5% | ▲486.6% |
| Bottom Line Profit Margin | -5.6% | ▲153.5% | ▲486.6% |
| Current Ratio | 9.068 | ▼-0.439 | ▼-7.134 |
| Quick Ratio | 9.068 | ▼-0.439 | ▼-7.134 |
| Solvency Ratio | -0.033 | ▲0.313 | ▲0.244 |
| Cash Ratio | 6.167 | ▲3.458 | ▼-2.506 |
| Price To Earnings Ratio | -70.261 | ▼-68.536 | ▼-52.294 |
| Price To Earnings Growth Ratio | 0.772 | ▲0.663 | ▲0.629 |
| Forward Price To Earnings Growth Ratio | 0.772 | ▲0.663 | ▲0.629 |
| Price To Earnings Diluted Ratio | -70.261 | ▼-68.536 | ▼-52.294 |
| Price To Earnings Diluted Growth Ratio | 0.772 | ▲0.663 | ▲0.629 |
| Price To Book Ratio | 24.137 | ▲20.601 | ▲16.929 |
| Price To Sales Ratio | 3.828 | ▲1.083 | ▼-15.293 |
| Price To Free Cash Flow Ratio | 45.800 | ▲47.647 | ▲41.904 |
| Price To Operating Cash Flow Ratio | 45.598 | ▲47.450 | ▲41.835 |
| Debt To Assets Ratio | 0.039 | ▼-0.725 | ▼-0.142 |
| Debt To Equity Ratio | 0.379 | ▼-4.834 | ▼-0.806 |
| Debt To Capital Ratio | 0.275 | ▼-0.564 | ▼-0.006 |
| Long Term Debt To Capital Ratio | 0.244 | ▼-0.589 | ▲0.029 |
| Financial Leverage Ratio | 9.793 | ▲2.966 | ▲4.615 |
| Working Capital Turnover Ratio | 0.672 | ▲0.431 | ▲0.449 |
| Operating Cash Flow Ratio | 0.510 | ▲3.489 | ▲2.784 |
| Operating Cash Flow Sales Ratio | 0.084 | ▲1.567 | ▲3.348 |
| Free Cash Flow Operating Cash Flow Ratio | 0.996 | ▼-0.007 | ▼-0.012 |
| Debt Service Coverage Ratio | 0.865 | ▲2.648 | ▲11.460 |
| Interest Coverage Ratio | 0.600 | ▲2.894 | ▲11.684 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲70.305 | ▲14.061 |
| Operating Cash Flow Coverage Ratio | 1.396 | ▲1.762 | ▲3.741 |
| Capital Expenditure Coverage Ratio | 226.402 | ▲604.439 | ▲334.504 |
| Dividend Paid And Capex Coverage Ratio | 226.402 | ▲604.439 | ▲334.504 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 9.734 | ▲15.093 | ▲10.912 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $898.1M | $250.6M | $384.5M | $581.9M | $635.6M | |
| Enterprise value | $674.1M | $497.0M | $366.3M | $530.0M | $160.8M | |
| EV / Sales | 2.87x | 5.45x | 21.35x | 51.52x | 2.54x | |
| EV / Op. cash flow | 34.22x | -3.67x | -3.03x | -7.20x | -3.50x | |
| EV / Free cash flow | 34.37x | -3.66x | -3.01x | -7.17x | -3.40x | |
| EV / EBITDA | 9.73x | -5.36x | -2.34x | -5.04x | -2.89x | |
| Net debt / EBITDA | -3.24x | -2.66x | 0.12x | 0.49x | 8.52x | |
| Current ratio | 9.07x | 9.51x | 10.87x | 17.16x | 34.40x | |
| Income quality | 0.40x | 0.93x | 0.74x | 0.57x | 0.80x | |
| Graham net-net | $0 | $0 | $1 | $3 | $10 | |
| Tax burden | 101.3% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | -19.6% | 152.6% | 104.2% | 119.6% | 100.0% | |
| Working capital | $311.6M | $386.4M | $369.4M | $421.2M | $537.8M | |
| Invested capital | $325.5M | $402.7M | $387.7M | $441.1M | $559.6M | |
| Return on assets | -3.6% | -30.0% | -36.2% | -21.1% | -9.0% | |
| Operating ROA | 11.3% | -24.6% | -30.9% | -18.4% | -10.7% | |
| Return on tangible assets | -3.6% | -30.0% | -36.2% | -21.1% | -9.0% | |
| Return on equity | -35.6% | -204.9% | -185.7% | -49.1% | -16.2% | |
| Return on invested capital | 14.6% | -26.1% | -39.5% | -19.7% | -9.0% | |
| Return on capital employed | 14.7% | -26.2% | -39.6% | -19.7% | -9.1% | |
| Earnings yield | -1.5% | -58.0% | -42.6% | -22.1% | -9.1% | |
| Free cash flow yield | 2.2% | -54.1% | -31.6% | -12.7% | -7.4% | |
| Capex / Op. cash flow | 0.4% | -0.3% | -0.7% | -0.5% | -3.0% | |
| Capex / Depreciation | 3.6% | 14.9% | 34.0% | 15.3% | 65.4% | |
| Capex / Sales | 0.0% | 0.4% | 4.7% | 3.5% | 2.2% | |
| SG&A / Sales | 21.6% | 46.4% | 244.5% | 356.2% | 34.0% | |
| R&D / Sales | 58.0% | 179.5% | 813.8% | 863.2% | 155.9% | |
| Stock comp / Sales | 15.4% | 37.3% | 193.5% | 265.9% | 24.3% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 53d | 163d | 146d | 50d | 5d | |
| Days payables outstanding | 583d | 9d | 13d | 11d | 6d | |
| Operating cycle | 53d | 163d | 146d | 50d | 5d | |
| Cash conversion cycle | -530d | 154d | 133d | 39d | -1d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-21 AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.34 per share a year ago.
- 2026-09-21 Anaptys Announces Second Quarter and Transitional Fiscal Year 2026 Financial Results and Provides Business Update SAN DIEGO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with Tesaro, a GSK company, and Quimilza (imsidolimab) with Vanda, today reported financial results for the second quarter and transitional fiscal year ended June 30, 2026, and provided a business update.
- 2026-09-01 Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.
- 2026-09-01 16,500 Shares in AnaptysBio, Inc. $ANAB Bought by Canada Pension Plan Investment Board Canada Pension Plan Investment Board purchased a new stake in AnaptysBio, Inc. (NASDAQ: ANAB) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 16,500 shares of the biotechnology company''s stock, valued at approximately $1,114,000. Canada Pension Plan Investment Board owned
- 2026-08-24 GSK''s sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer GSK''s Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
- 2026-07-29 AnaptysBio: The Royalty Waterfall Is About To Reverse AnaptysBio is now a focused royalty management company, with its value tied primarily to Jemperli royalties from GSK. Post-spin, ANAB operates virtually with a 95% targeted EBIT margin and over $140M net cash, eliminating prior R&D burn. Jemperli royalties escalate with sales, and once the Sagard obligation is paid (expected by mid-2027), ANAB will retain high-margin, growing royalty streams.
- 2026-07-19 AnaptysBio (NASDAQ:ANAB) Stock Price Up 5.3% – Still a Buy? AnaptysBio, Inc. (NASDAQ: ANAB - Get Free Report) rose 5.3% during mid-day trading on Friday. The company traded as high as $56.54 and last traded at $57.00. 47,244 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 753,749 shares. The stock had previously closed at $54.15. Analysts Set
- 2026-07-14 GSK''s Jemperli Delivers Promising Interim Data in Rectal Cancer GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.